Subscribe to news

Press Releases

07.03.2013
OJSC, one of the leading Russian biotech companies, today announced the decision of its Board of Directors on the lists of candidates to the Board of Directors and the Audit Commission of the Company to be elected at the Annual General Shareholders’ Meeting.
28.02.2013
Human Stem Cells Institute, one of the leading Russian biotech companies, today announced that on February 26, 2013, the Ministry of Healthcare of Ukraine issued marketing authorization to HSCI for Neovasculgen®, a drug intended for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI).
02.11.2012
Human Stem Cells Institute OJSC, one of Russia’s leading biotech companies, today announced its unaudited results for the first nine months of 2012 in accordance with Russian Accounting Standards (RAS)
21.09.2012
The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies, today announced that certification of Neovasculgen’s first batches has been completed and the drug will go to market before the end of September.
09.08.2012
August 3 Moscow Bank of Sberbank of Russia and OJSC HSCI - completed the signing of the financing agreements of $ 75 million.
07.08.2012
OJSC HSCI, today announced its unaudited results for the first half of 2012 in accordance with the Russian Accounting Standards (RAS).
06.08.2012
OJSC HSCI, today announced its audited consolidated financial results for the full year ended December 31, 2011 in accordance with International Financial Reporting Standards (IFRS).
22.06.2012
OJSC HSCI, one of Russia’s leading biotech companies (hereinafter – the Company), announces the results of the Annual General Shareholders’ Meeting (AGM) held on June 21, 2012, in Moscow.
01.06.2012
On May 24 the Federal Service for Supervision of Healthcare and Social Development of the Russian Federation (Roszdravnadzor) issued the Human Stem Cells Institute marketing authorization (Registration Certificate No. FSZ 2012/12193) for a device called Celution 800 System, a closed system which processes human adipose (fat) tissue. The apparatus is manufactured by the US-based Cytori Therapeutiсs. The beginning of sales planned for the third quarter of 2012.
21.05.2012
OJSC HSCI, one of Russia’s leading biotech companies, today announced the decision of the Company’s Board of Directors on the agenda of the Annual General Shareholders’ Meeting on the results of 2011.